Advances in clinical research on rtA181 mutation in hepatitis B virus
10.3760/cma.j.issn.1007-3418.2017.01.020
- VernacularTitle: 乙型肝炎病毒rtA181位点突变的临床研究进展
- Author:
Xiaoling GONG
1
;
Ren LIU
2
;
Yingxia LIU
3
;
Yi ZHANG
1
Author Information
1. Department of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
2. BGI-Shenzhen, Shenzhen 518085, China
3. The Third Hospital of Shenzhen, Shenzhen 518112, China
- Publication Type:Review
- Keywords:
Hepatitis B virus;
Mutation;
Rescue therapy
- From:
Chinese Journal of Hepatology
2017;25(1):69-72
- CountryChina
- Language:Chinese
-
Abstract:
Nowadays, nucleos(t)ide analogues (NAs) are important drugs for the treatment of chronic hepatitis B and can suppress the virus through inhibiting the activity of hepatitis B virus (HBV) polymerase. However, rtA181 mutation in HBV can reduce the sensitivity of HBV to various NAs, which brings new challenges to antiviral therapy. This article briefly introduces the research advances in the clinical detection rate of rtA181 mutation and its influence on therapeutic effect and prognosis.
